Get the Stockscreener App
0.52
0.39%
0.002
After Hours:
.51
-0.01
-1.92%
Altamira Therapeutics Ltd Stock (CYTO) Forecast
The Altamira Therapeutics Ltd (CYTO) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $539.44, representing a +103.64K% increase from the current price of $0.52. The highest analyst price target is $558.35, and the lowest is $520.53.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CYTO Price Target
Average 558.54
(+107.31K% Upside)
Is Altamira Therapeutics Ltd (CYTO) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 37.28 | Neutral |
| STOCH(9,6) | 33.53 | Neutral |
| STOCHRSI(14) | 84.62 | Sell |
| MACD(12,26) | -0.0533 | Buy |
| ADX(14) | 53.11 | Sell |
| William %R | -61.11 | Neutral |
| CCI(14) | -35.39 | Neutral |
Buy: 1
Sell: 2
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.5073
Buy
|
0.5186
Buy
|
| MA20 |
0.5552
Sell
|
0.5538
Sell
|
| MA50 |
0.6823
Sell
|
0.6832
Sell
|
| MA100 |
0.9024
Sell
|
0.9464
Sell
|
| MA200 |
1.3255
Sell
|
1.8267
Sell
|
Buy: 2
Sell: 8
Neutral: 0
Summary: Sell
According to our latest analysis, CYTO could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 10 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on CYTO, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 37.28 indicates that CYTO is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 33.53 indicates that CYTO is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 84.62 indicates that CYTO is oversold. This suggests that CYTO price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 53.11 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -35.39 indicates that CYTO is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term CYTO price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Altamira Therapeutics Ltd financial reports and earnings history, Altamira Therapeutics Ltd (CYTO) stock could reach $487.72 by 2030, $6,034.28 by 2040 and $8,592.46 by 2050. See the projected annual prices until 2050 of the Altamira Therapeutics Ltd stock below:
- Altamira Therapeutics Ltd (CYTO) is expected to reach an average price of $2,730.15 in 2035, with a high prediction of $2,808.43 and a low estimate of $2,754.11. This indicates an $524.93K% rise from the last recorded price of $0.52.
- Altamira Therapeutics Ltd (CYTO) stock is projected to chart a bullish course in 2040, with an average price target of $6,070.28, representing an $1.17M% surge from its current level. The forecast ranges from a conservative $43.53 to a sky-high $6,034.28.
- Our analysts predict Altamira Therapeutics Ltd (CYTO) to jump 664.04K% by 2045, soaring from $3,454.53 to an average price of $3,453.53, potentially reaching $3,535.36. While $3,454.53 is the low estimate, the potential upside is significant.
- Altamira Therapeutics Ltd (CYTO) stock is expected to climb by 2050, reaching an average of $8,448.80, a $1.62M% jump from its current level. However, a wide range of estimates exists, with high and low targets of $8,592.46 and $8,460.80, respectively, highlighting the market's uncertainty.
Altamira Therapeutics Ltd Stock (CYTO) Year by Year Forecast
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2024
Our forecast for CYTO stock price in 2024 now indicates an average price target of $279.85 with a high forecast of $558.35 and a low forecast of $1.35. The average prediction reflects an increase of +53,717% from the last recorded price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2024 | $580.27 | $520.53 | $558.35 | +111.49K% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2025
Altamira Therapeutics Ltd Stock (CYTO) is expected to reach an average price of $547.56 in 2025, with a high prediction of $609.90 and a low estimate of $485.22. This indicates an +105.20K% rise from the last recorded price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $493.37 | $525.37 | $563.03 | +94,780% |
| February, 2025 | $521.03 | $507.19 | $487.79 | +100.10K% |
| March, 2025 | $527.66 | $552.40 | $541.61 | +101.37K% |
| April, 2025 | $601.08 | $568.03 | $589.88 | +115.49K% |
| May, 2025 | $605.50 | $625.45 | $609.90 | +116.34K% |
| June, 2025 | $602.08 | $615.03 | $603.48 | +115.68K% |
| July, 2025 | $588.71 | $587.29 | $585.11 | +113.11K% |
| August, 2025 | $595.57 | $585.92 | $583.53 | +114.43K% |
| September, 2025 | $521.95 | $537.95 | $584.13 | +100.27K% |
| October, 2025 | $523.77 | $526.15 | $530.57 | +100.63K% |
| November, 2025 | $522.19 | $516.58 | $512.98 | +100.32K% |
| December, 2025 | $474.82 | $485.22 | $504.60 | +91,211% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2026
The predicted value for Altamira Therapeutics Ltd (CYTO) in 2026 is set at an average of $346.88. Estimates vary from a peak of $505.90 to a trough of $187.87, indicating an +66,608% surge from the present price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $493.64 | $493.84 | $505.90 | +94,831% |
| February, 2026 | $469.46 | $474.06 | $484.36 | +90,181% |
| March, 2026 | $464.08 | $466.28 | $472.68 | +89,146% |
| April, 2026 | $432.31 | $438.11 | $444.89 | +83,036% |
| May, 2026 | $406.53 | $409.13 | $422.31 | +78,078% |
| June, 2026 | $378.77 | $379.64 | $398.13 | +72,740% |
| July, 2026 | $349.47 | $350.37 | $371.37 | +67,106% |
| August, 2026 | $319.81 | $320.09 | $341.38 | +61,403% |
| September, 2026 | $284.72 | $285.42 | $312.19 | +54,654% |
| October, 2026 | $255.69 | $256.24 | $277.02 | +49,071% |
| November, 2026 | $227.86 | $228.01 | $248.34 | +43,719% |
| December, 2026 | $187.51 | $187.87 | $220.58 | +35,959% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Altamira Therapeutics Ltd (CYTO) is $774.83, with a high forecast of $1,542.17 and a low forecast of $7.4826. This indicates an +148.91K% increase from the last price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $160.83 | $161.76 | $173.69 | +30,828% |
| February, 2027 | $132.73 | $132.82 | $153.31 | +25,424% |
| March, 2027 | $95.95 | $96.02 | $125.29 | +18,352% |
| April, 2027 | $66.44 | $66.54 | $88.42 | +12,677% |
| May, 2027 | $36.76 | $36.79 | $59.04 | +6,970% |
| June, 2027 | $1,212.76 | $7.4826 | $1,176.76 | +233.12K% |
| July, 2027 | $1,301.60 | $1,301.97 | $1,256.39 | +250.21K% |
| August, 2027 | $1,506.44 | $1,390.81 | $1,338.44 | +289.60K% |
| September, 2027 | $1,580.49 | $1,575.65 | $1,536.49 | +303.84K% |
| October, 2027 | $1,437.33 | $1,537.33 | $1,533.66 | +276.31K% |
| November, 2027 | $1,594.17 | $1,506.54 | $1,542.17 | +306.47K% |
| December, 2027 | $1,508.23 | $1,429.81 | $1,503.38 | +289.94K% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2028
In 2028, Altamira Therapeutics Ltd (CYTO) is projected to reach an average price of $1,347.93, with a high projection of $1,528.70 and a low estimate of $1,167.16. This indicates an +259.12K% rise from the last price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1,501.07 | $1,513.07 | $1,489.44 | +288.57K% |
| February, 2028 | $1,601.91 | $1,530.28 | $1,528.70 | +307.96K% |
| March, 2028 | $1,427.96 | $1,451.96 | $1,500.33 | +274.51K% |
| April, 2028 | $1,436.80 | $1,418.38 | $1,397.21 | +276.21K% |
| May, 2028 | $1,425.25 | $1,437.45 | $1,423.22 | +273.99K% |
| June, 2028 | $1,455.29 | $1,420.06 | $1,427.12 | +279.76K% |
| July, 2028 | $1,412.37 | $1,415.29 | $1,424.95 | +271.51K% |
| August, 2028 | $1,342.58 | $1,350.58 | $1,388.95 | +258.09K% |
| September, 2028 | $1,319.46 | $1,331.42 | $1,329.00 | +253.64K% |
| October, 2028 | $1,300.47 | $1,308.27 | $1,295.05 | +249.99K% |
| November, 2028 | $1,212.32 | $1,200.71 | $1,269.60 | +233.04K% |
| December, 2028 | $1,162.16 | $1,167.16 | $1,190.33 | +223.39K% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2029
The 2029 price forecast for Altamira Therapeutics Ltd Stock (CYTO) is $821.73 on average, with a high prediction of $1,140.37 and a low estimate of $503.09. This represents an +157.92K% increase from the previous price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1,104.21 | $1,112.21 | $1,140.37 | +212.25K% |
| February, 2029 | $1,086.65 | $1,063.64 | $1,068.42 | +208.87K% |
| March, 2029 | $1,033.49 | $1,034.09 | $1,069.53 | +198.65K% |
| April, 2029 | $992.53 | $993.32 | $1,016.70 | +190.77K% |
| May, 2029 | $927.18 | $928.28 | $977.15 | +178.20K% |
| June, 2029 | $871.74 | $872.22 | $905.99 | +167.54K% |
| July, 2029 | $814.04 | $814.66 | $856.35 | +156.45K% |
| August, 2029 | $748.11 | $748.51 | $799.07 | +143.77K% |
| September, 2029 | $690.76 | $691.16 | $732.92 | +132.74K% |
| October, 2029 | $617.21 | $617.65 | $674.77 | +118.59K% |
| November, 2029 | $560.37 | $560.55 | $602.22 | +107.66K% |
| December, 2029 | $502.71 | $503.09 | $545.36 | +96,575% |
Altamira Therapeutics Ltd Stock (CYTO) Price Forecast for 2030
Altamira Therapeutics Ltd Stock (CYTO) is expected to reach an average price of $1,335.62 in 2030, with a high forecast of $2,654.74 and a low forecast of $16.50. This signifies an +256.75K% surge from the last price of $0.52.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $426.54 | $430.26 | $487.72 | +81,927% |
| February, 2030 | $364.78 | $367.52 | $407.77 | +70,050% |
| March, 2030 | $310.70 | $310.72 | $350.81 | +59,650% |
| April, 2030 | $252.81 | $252.88 | $295.78 | +48,518% |
| May, 2030 | $178.83 | $178.94 | $237.96 | +34,291% |
| June, 2030 | $119.82 | $119.93 | $163.46 | +22,943% |
| July, 2030 | $45.92 | $46.26 | $103.27 | +8,730% |
| August, 2030 | $2,460.96 | $16.50 | $2,391.14 | +473.16K% |
| September, 2030 | $2,504.22 | $2,490.40 | $2,448.59 | +481.48K% |
| October, 2030 | $2,725.29 | $2,668.03 | $2,640.20 | +523.99K% |
| November, 2030 | $2,680.55 | $2,684.55 | $2,654.74 | +515.39K% |
| December, 2030 | $2,535.82 | $2,587.82 | $2,483.82 | +487.56K% |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):